Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
Open Access
- 20 August 2018
- journal article
- review article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 5 (1) , e000209
Abstract
Background Genotype 3 (GT3) is a common chronic hepatitis C (CHC) genotype in Asia. Direct-acting antiviral (DAA) regimens have high cure rates, but real-world results are limited for Asia. Aim To determine the real-world effectiveness of DAAs for patients with CHC GT3 in Asia. Methods A systematic search was performed in PubMed (including MEDLINE), Embase, and selected international meeting abstract repositories. Eligible studies were postmarketing observational studies from Asia with the primary outcome of sustained virological response 12 weeks after completion of treatment (SVR12). Results A total of 15 studies with 4230 patients yielded a pooled SVR12 of 92.7%. High heterogeneity (I 2=93.2%, PPP=0.89). Twenty-four weeks of sofosbuvir+ribavirin dual therapy was the most commonly used regimen which led to similar SVR12 (OR=1.1, P=0.73) but lower adverse event rate than 12 weeks of sofosbuvir+ribavirin+pegylated interferon triple therapy. Conclusion Sofosbuvir+ribavirin for 24 weeks is the most widely used and generally well-tolerated DAA therapy in Asia. However, its effectiveness is not optimal in GT3 patients with cirrhosis.Keywords
This publication has 40 references indexed in Scilit:
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis CDigestive and Liver Disease, 2014
- Metaprop: a Stata command to perform meta-analysis of binomial dataArchives of Public Health, 2014
- Is genotype 3 of the hepatitis C virus the new villain?Hepatology, 2014
- Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagramSystematic Reviews, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3New England Journal of Medicine, 2014
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsNew England Journal of Medicine, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialThe Lancet Infectious Diseases, 2013
- Measuring inconsistency in meta-analysesBMJ, 2003